Figure 2.
PP2A–mediated gene expression changes in response to OSU-2S. (A) Differential expression of genes in MV4-11 cells (5 µM, 8 hours) treated with OSU-2S, compared with vehicle control (Veh). (B) Major pathways predicted to be differentially regulated from OSU-2S–mediated changes in the transcriptome. (C) Gene Set Enrichment Analysis enrichment plot showing negative correlation of Myc and E2F targets with OSU-2S-treated RNA expression. Fold change (log) modulation of cell cycle regulators and differentiation genes in MV4-11 (D) and HL-60 (E) cells treated with OSU-2S (5 μM, 8 hours) normalized to Veh-treated cells. (F) Fold change (log) modulation of cell cycle regulators and differentiation genes in primary AML cells (AML 17-AML 20) treated with OSU-2S (3.5 μM, 16 hours) normalized to Veh-treated cells. *P < .05; **P < .01; ***P < .001.

PP2A–mediated gene expression changes in response to OSU-2S. (A) Differential expression of genes in MV4-11 cells (5 µM, 8 hours) treated with OSU-2S, compared with vehicle control (Veh). (B) Major pathways predicted to be differentially regulated from OSU-2S–mediated changes in the transcriptome. (C) Gene Set Enrichment Analysis enrichment plot showing negative correlation of Myc and E2F targets with OSU-2S-treated RNA expression. Fold change (log) modulation of cell cycle regulators and differentiation genes in MV4-11 (D) and HL-60 (E) cells treated with OSU-2S (5 μM, 8 hours) normalized to Veh-treated cells. (F) Fold change (log) modulation of cell cycle regulators and differentiation genes in primary AML cells (AML 17-AML 20) treated with OSU-2S (3.5 μM, 16 hours) normalized to Veh-treated cells. *P < .05; **P < .01; ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal